{"classes":[{"categories":[{"measurements":[{"comment":"The SD was not estimable due to single participant with event.","groupId":"OG000","spread":"NA","value":"4.79"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.3","value":"36.3"},{"groupId":"OG001","spread":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"330"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day 1, 1 Hour Post-Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.1","value":"15.6"},{"groupId":"OG001","spread":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"321"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day 1, 4 Hours Post-Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.5","value":"6.83"},{"groupId":"OG001","spread":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"335"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day 14, Pre-Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.4","value":"2.4"},{"groupId":"OG001","spread":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"331"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Cycle 2 Day 1, Pre-Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.44","value":"7.12"},{"groupId":"OG001","spread":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"324"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Cycle 2 Day 14, Pre-Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.69","value":"2.48"},{"groupId":"OG001","spread":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"329"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Cycle 3 Day 1, Pre-Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.35","value":"2.41"},{"groupId":"OG001","spread":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"319"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Cycle 4 Day 1, Pre-Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.49","value":"2.42"},{"groupId":"OG001","spread":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"307"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Cycle 5 Day 1, Pre-Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.89","value":"2.57"},{"groupId":"OG001","spread":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Cycle 6 Day 1, Pre-Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.79","value":"2.71"},{"groupId":"OG001","spread":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 7 Day 1, Pre-Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.47","value":"2.37"},{"groupId":"OG001","spread":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"268"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 8 Day 1, Pre-Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.13","value":"2.51"},{"groupId":"OG001","spread":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"262"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Cycle 9 Day 1, Pre-Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.98","value":"2.82"},{"groupId":"OG001","spread":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 10 Day 1, Pre-Dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"335"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Ixazomib 4 mg, capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until PD or unacceptable toxicity, whichever occurred first up to EOT (up to approximately 42.9 months).","id":"OG000","title":"Ixazomib+ Lenalidomide + Dexamethasone"},{"description":"Ixazomib placebo-matching capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until PD or unacceptable toxicity, whichever occurred first (up to approximately 41 months).","id":"OG001","title":"Placebo + Lenalidomide + Dexamethasone"}],"paramType":"MEAN","populationDescription":"Safety population is defined as all subjects who received at least 1 dose of any study drug. Overall number analyzed is the number of participants available for analysis. Number analyzed is the number of participants available for analysis at the given timepoint.","reportingStatus":"POSTED","timeFrame":"Pre-dose and post-dose at multiple timepoints up to Cycle 10 Day 1 (each cycle length = 28 days)","title":"Plasma Concentration Over Time for Ixazomib","type":"SECONDARY","unitOfMeasure":"μg/mL"}